Disrupting the DNA damage response has become a compelling therapeutic strategy in oncology in recent years and WEE1 inhibitors are among the most promising drugs being developed within this class.  Ahead of the European Society for Medical Oncology (ESMO) Congress 2026, this panel will cover the underlying biology of WEE1, the selectivity challenge that has shaped the class, and what to watch in the months ahead, across scientific, clinical, and market perspectives.  Moderated by Solomon Wilcots, NFL broadcaster and former player for the Cincinnati Bengals, the panel will feature the following participants:

• Alex Spira, Director of the Thoracic and Phase I Program at the Virginia Cancer Specialists Research Institute, Chief Scientific Officer of NEXT Oncology and Clinical Assistant Professor at Johns Hopkins School of Medicine.
• Kevin DeGeeter Managing Director in equity research at Ladenburg Thalmann & Co. Inc.
• Eugene Kennedy, Chief Medical Advisor of Aprea Therapeutics, Inc.